Table 1.
Clinicopathologic features of 117 patients evaluated with [68Ga]Ga-PSMAHBED-CC conjugate 11 ligand PET-CT or PET-MRI for biochemical recurrence after radical prostatectomy for clinically non-metastatic prostate cancer with curative intent
| Age (years), median (IQR) | 74 (68–76) |
| Pelvic lymphadenectomy performed at time of RP, n (%) | 112 (95.7) |
| Pathological stage after RP, n (%) | |
| pT2 | 46 (39.3) |
| pT3a | 32 (27.4) |
| pT3b | 37 (31.6) |
| pT4 | 2 (1.7) |
| Positive LN at RP, n (%) | 11 (9.8) |
| Positive surgical margins, n (%) | 49 (41.9) |
| Gleason score at RP, n (%) | |
| 6 | 15 (12.8) |
| 7 | 56 (47.9) |
| ≥8 | 46 (39.3) |
| Post surgery RT, n (%) | 69 (59.0) |
| Adjuvant RT | 27 (23.1) |
| Salvage RT | 42 (35.9) |
| PSMA application (MBq), median (IQR) | 180 (167–192) |
IQR interquartile range, RP radical prostatectomy, LN lymph node, RT radiotherapy, PSMA prostate-specific membrane antigen, MBq megabecquerel